Twillman on Hydrocodone

Play Audio


If the FDA tightens restrictions on Hydrocodone, Bob Twillman, Director of Policy and Advocacy for the American Academy of Pain Management worries that patients who rely on this Opioid to relieve chronic pain are going to suffer across the board:

Twillman:  “we’re concerned about how they are going to compensate for the 26 million automatic refills that happened at pharmacies with that medication last year. We’re concerned that could result in up to 26 million additional office visits being required so that people can get written prescriptions for those medications. The cost of that would be phenomenal”

An estimated three-quarters of a billion dollars, according to Twillman, not including the cost of taking a day off from work, getting to the doctor’s office and the stress that goes along with it.